+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Evaluation of Systemic Inflammatory Response Biomarkers in Patients Receiving Chemotherapy for Unresectable and Recurrent Advanced Gastric Cancer



Evaluation of Systemic Inflammatory Response Biomarkers in Patients Receiving Chemotherapy for Unresectable and Recurrent Advanced Gastric Cancer



Oncology 90(6): 321-326



The present study sought to evaluate an inflammation-based prognostic score (Glasgow prognostic score, GPS) and the neutrophil to lymphocyte ratio (NLR) as prognostic factors in patients receiving chemotherapy for advanced gastric cancer. The study enrolled 224 patients who received chemotherapy for advanced gastric cancer at the Kochi Medical School from 2007 to 2014. Clinicopathological information and systemic inflammatory response data were obtained to investigate associations between baseline cancer-related prognostic variables and survival outcomes. The median survival time was significantly higher for patients with intestinal-type compared to diffuse-type histology (p = 0.039), a GPS 0 score compared to GPS 1 or 2 score (p = 0.004), and lower compared to higher NLR 4 (p = 0.002). Multivariate survival analysis identified high NLR 4 (HR 1.651; 95% CI 1.187-2.297; p = 0.003) and diffuse-type histology (HR 1.645; 95% CI 1.025-2.639; p = 0.039) as significant independent predictors associated with worse prognosis in the studied group of cancer patients. NLR and histological type are independent prognostic factors for patients receiving chemotherapy for unresectable and recurrent gastric cancer.

(PDF emailed within 0-6 h: $19.90)

Accession: 057809687

Download citation: RISBibTeXText

PMID: 27225990

DOI: 10.1159/000446373


Related references

Treatment features of systemic chemotherapy in young adults with unresectable advanced or recurrent gastric cancer. Cancer Management and Research 10: 5283-5290, 2018

Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer. Bmc Cancer 11: 489, 2012

Second-line chemotherapy with paclitaxel and doxifluridine after failure of S-1 in elderly patients with unresectable advanced or recurrent gastric cancer. Journal of Cancer Research and Clinical Oncology 137(10): 1499-1504, 2011

Combination of irinotecan and Mitomycin C as second-line chemotherapy for patients with unresectable advanced or recurrent gastric cancer in clinical practice. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 36(8): 1293-1297, 2009

Evaluation of immunity in elderly patients with unresectable gastric cancer receiving S-1/Lentinan combination chemotherapy. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 41(10): 1264-1266, 2014

Evaluation of a trastuzumab-containing treatment regimen for patients with unresectable advanced or recurrent gastric cancer. Molecular and Clinical Oncology 5(1): 74-78, 2016

JCOG trials of systemic chemotherapy for unresectable or recurrent gastric cancer. Gastric Cancer 12(1 Supplement): 43-49, 2009

Circulating free plasma tumor DNA in patients with advanced gastric cancer receiving systemic chemotherapy. Bmc Clinical Pathology 18: 12, 2018

ISY4-5Perspectives of systemic chemotherapy for unresectable and recurrent gastric cancer Cytotoxic agent. Annals of Oncology 26(Suppl 7): Vii12.2-Vii12, 2015

Complications in advanced or recurrent gastric cancer patients with peritoneal metastasis during and after palliative systemic chemotherapy. Molecular and Clinical Oncology 3(3): 539-542, 2015

Indication of Palliative Gastrojejunostomy for Unresectable Advanced Gastric Cancer with Obstruction from the View Point of Preoperative Inflammatory Biomarkers. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 45(2): 336-338, 2018

Tolerable evaluation for chemotherapy with S-1 plus cisplatin in elderly patients with advanced and recurrent gastric cancer. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 39(8): 1209-1214, 2012

Hepatic arterial infusion chemotherapy prior to standard systemic chemotherapy in patients with highly advanced unresectable liver metastases from colorectal cancer: a report of three patients. Acta Medica Okayama 65(1): 49-53, 2011

Pharmacogenomic prediction of response in advanced gastric cancer (AGC) patients receiving 5-Fluorouracil (FU)/leucovorin (LV)/oxaliplatin (OX) as first-line palliative chemotherapy. Journal of Clinical Oncology 23(16_suppl): 3060-3060, 2016

Predictive value of the ERCC1 expression for treatment response and survival in advanced gastric cancer patients receiving cisplatin-based first-line chemotherapy. Cancer Research and Treatment 42(2): 101-106, 2010